Bionik Laboratories Corp Stock Gross Profit
Bionik Laboratories Corp fundamentals help investors to digest information that contributes to Bionik Laboratories' financial success or failures. It also enables traders to predict the movement of Bionik Pink Sheet. The fundamental analysis module provides a way to measure Bionik Laboratories' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionik Laboratories pink sheet.
Bionik |
Bionik Laboratories Corp Company Gross Profit Analysis
Bionik Laboratories' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Bionik Laboratories Gross Profit | 953.26 K |
Most of Bionik Laboratories' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionik Laboratories Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Bionik Laboratories Corp reported 953.26 K of gross profit. This is 99.96% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Bionik Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionik Laboratories' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bionik Laboratories could also be used in its relative valuation, which is a method of valuing Bionik Laboratories by comparing valuation metrics of similar companies.Bionik Laboratories is currently under evaluation in gross profit category among its peers.
Bionik Fundamentals
| Return On Equity | -7.83 | |||
| Return On Asset | -0.64 | |||
| Operating Margin | (3.30) % | |||
| Current Valuation | 4.84 M | |||
| Shares Outstanding | 6.88 M | |||
| Shares Owned By Insiders | 61.64 % | |||
| Shares Owned By Institutions | 1.18 % | |||
| Price To Earning | (3.60) X | |||
| Price To Book | 8.04 X | |||
| Price To Sales | 3.82 X | |||
| Revenue | 1.27 M | |||
| Gross Profit | 953.26 K | |||
| EBITDA | (9.48 M) | |||
| Net Income | (10.41 M) | |||
| Cash And Equivalents | 1.33 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 503.47 K | |||
| Debt To Equity | 0.32 % | |||
| Current Ratio | 2.32 X | |||
| Book Value Per Share | (0.08) X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (1.78) X | |||
| Number Of Employees | 12 | |||
| Beta | -1.02 | |||
| Market Capitalization | 4.27 M | |||
| Total Asset | 4.68 M | |||
| Retained Earnings | (10.65 M) | |||
| Working Capital | 891 K | |||
| Current Asset | 7.15 M | |||
| Current Liabilities | 6.26 M | |||
| Z Score | -4.6 | |||
| Net Asset | 4.68 M |
About Bionik Laboratories Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionik Laboratories Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionik Laboratories using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionik Laboratories Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Bionik Pink Sheet
Bionik Laboratories financial ratios help investors to determine whether Bionik Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bionik with respect to the benefits of owning Bionik Laboratories security.